{"id":"W4393238711","doi":"10.1016/s2352-3026(24)00045-0","title":"Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Manitoba","funders":"Janssen Research and Development; National Institutes of Health; Incyte; bluebird bio; National Center for Advancing Translational Sciences; Health Resources and Services Administration; Agios Pharmaceuticals; Chiesi Farmaceutici; Bayer Corporation; CSL Behring; Novo Nordisk; Teva Pharmaceutical Industries; United Therapeutics Corporation; Celgene; Bayer HealthCare; Sanofi; Alexion Pharmaceuticals; Penn State College of Medicine; University of Pittsburgh; National Heart, Lung, and Blood Institute; Vifor Pharma; Pfizer","keywords":"Medicine; Riociguat; Placebo; Proteinuria; Internal medicine; Sickle cell anemia; Disease; Clinical trial; Anemia; Gastroenterology; Pulmonary hypertension; Kidney; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001297797,0.002276813,0.00448492,0.000521929,0.0003909091,0.001172603,0.001024005,0.002503955,0.009314121],"category_scores_gemma":[0.001467817,0.0007614727,0.002261144,0.0004680893,0.001292413,0.00121364,0.000435993,0.003525011,0.001294556],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006277828,"about_ca_system_score_gemma":0.0006976467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001420668,"about_ca_topic_score_gemma":0.002849089,"domain_scores_codex":[0.9994676,0.0002473222,0.00002742019,0.0001166851,0.00003303515,0.000108035],"domain_scores_gemma":[0.9995363,0.0001482674,0.00009484713,0.00003448732,0.00003138569,0.0001547574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9843429,0.001574528,0.0002277694,0.001273888,0.001128949,0.00004570421,0.00003667687,0.000156533,0.001654691,0.0001369242,0.001042467,0.008378955],"study_design_scores_gemma":[0.9889368,0.009626647,0.0004924744,0.00002795005,0.000299022,0.00001443275,0.00001226647,0.00009186126,0.0000811975,0.00007467547,0.0003345072,0.000008168132],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9516425,0.02802332,0.001704166,0.002362882,0.003084434,0.004647398,0.002316425,0.000560987,0.005657834],"genre_scores_gemma":[0.9683344,0.01183853,0.002114511,0.003420453,0.00110409,0.004389429,0.001680121,0.00006707922,0.007051261],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009314121,"threshold_uncertainty_score":0.03115886,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02517269675344845,"score_gpt":0.2861932875726454,"score_spread":0.2610205908191969,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}